Deming David H 4

What Happened

• David H. Deming, a director of Phio Pharmaceuticals Corp. (PHIO), received an award of 23,800 shares (reported as acquisition code A) on 2026-02-05. The reported price per share is $0.00, so the grant had no cash purchase price recorded. This is a restricted stock unit (RSU) award rather than an open-market purchase or sale.

Key Details

• Transaction date: 2026-02-05; Form 4 filed: 2026-02-06 (appears timely).
• Transaction type/code: Award/Grant (A); 23,800 shares acquired at $0.00 (no cash paid).
• Vesting/derivative note: Footnote F1 — these shares represent RSUs that will vest on the first annual anniversary of the grant.
• Ownership reporting: Footnote F2 indicates the reported ownership includes shares underlying unvested RSUs. The filing excerpt provided does not state the total shares beneficially owned after this grant.
• No indication of a sale, gift, or option exercise in this transaction.

Context

• RSU grants are common compensation for executives and directors; they do not involve an immediate cash outlay by the insider and typically vest over time. This award increases potential future ownership once vesting conditions are met but does not imply an immediate buy or sell signal.